Patent · US Active

Method for vaccination against a self-antigen in a human patient

US12290553B2 · kind B2 · utility

0Cited by

0References

10Claims

0Family size

Assignee

AC Immune SA · CH

Inventors

Gergana Galabova · Wien, AT
Sabine SCHMIDHUBER · Wien, AT
Achim Schneeberger · Fort Lauderdale, US
Arne Von Bonin · Hohen Neuendorf, DE
Dorian Winter · Wien, AT
Jana Zimmermann · Wien, AT

Key dates

Filing date	Nov 2, 2016
Grant date	May 6, 2025
Priority date	—
Expiry date	Oct 25, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/627
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a method for vaccination against a self-antigen in a human patient wherein a dose with an effective amount of a self-antigen is administered to the patient to elicit a primary immune response, characterised in that the patient is subjected to a boost administration of said self-antigen, wherein the amount of the self-antigen in the dose for the boost administration is higher than the amount of the self-antigen in the dose used in the administration for the primary immune response.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.